Heart Failure

Regular usage of cannabis may increase the risk of heart failure, stroke, or heart attack, even after adjusting for other cardiovascular disease risk factors.

Risk of atrial fibrillation with 1 of the independent predictors, including congestive heart failure and left atrial enlargement, resulted in greater than a 4-fold increased detection.

Although SGLT2 inhibitors are not a cure of diabetic kidney disease, this treatment can help reduce the risk and manage the disease either alone or with complementary therapies.

How pharmacy teams can remove cost barriers to cardiac care.

Anemic individuals with heart failure with preserved ejection fraction displayed unique pathophysiological features that led to reduced exercise capacity.

Sotagliflozin (Inpefa) is an orally administered dual SGLT1/2 inhibitor that reduces the risk of death due to heart failure.

BMS-986278 (Bristol Myers Squibb) is a potential first-in-class treatment for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis.

This marks the first time that experts have defined cardiovascular-kidney-metabolic syndrome, including the overlap of cardiovascular disease with kidney disease, type 2 diabetes, and obesity.

Patients under the care of psychiatric facilities, particularly those taking antipsychotic and antidepressant medications, face the risk of prolonged QTc intervals.

Study findings indicated that many health care facilities are recovering from the COVID-19 pandemic and shortage of staff, which has caused door-to-balloon times to lag.

Routine yoga therapy has shown endurance, strength, balance, symptom stability and quality of life improvements in individuals with heart failure.

An average patient with heart failure can take up to 6 medications for guideline-directed medical therapy; however, they may have other comorbidities that require pharmacologic management.

Heart disease prevention efforts should acknowledge non-biological factors that can cause issues within cardiovascular health rather than relying on decreasing socioeconomic disparities.

The Phase 2 KARDIA-1 Study met its primary endpoint of lower systolic blood pressure with the use of zilebesiran.

Black women had the highest rates of obesity-related cardiovascular disease deaths whereas other racial groups had more men experiencing obesity-related CVD deaths than women.

Results from the VALOR-HCM LTE trial at 56 weeks demonstrated that with longer follow-up, mavacamten continued to reduce patient eligibility for invasive septal reduction therapy.

After 1 year of treatment, semaglutide significantly improved physical function, which can improve quality of life outcomes and risk of death.

Ferric carboxymaltose was not found to have a significant impact on 6-minute walk distance, which is part of the primary outcome’s hierarchical composite of death and hospitalizations from heart failure.

Stressful life events and poor sleeping patterns are linked to the development of atrial fibrillation in older women.

Pharmacists can actively engage in the implementation of the Comprehensive Diagnostics and Examinations in Acute Coronary Syndromes pathway within the hospital or health care system.

Notably, 65% of the participants experiencing pain at the 2-month follow up were also experiencing pain at their 12-month follow up, suggesting persistent and long-term pain.

Session at NACDS Total Store Expo discusses how pharmacies can leverage their accessibility to decrease diet-related diseases through health and wellness.

Research shows a substantial difference between overall deaths of men and women at 43% and 28.2%, respectively, from cardiovascular disease associated with particulate matter.

Study shows that as patients with type 2 diabetes lost more teeth, their risk of heart failure grew.

Updated guidelines, comprehensive review, and an investment of resources into pediatric preventive cardiology programs could help provide successful care.